Personalised Medicine is an approach to healthcare that adapts prevention, diagnosis or treatment to the characteristics and needs of an individual rather than relying exclusively on a uniform strategy for everyone. Personalisation can incorporate biological factors such as genetics and biomarkers, but it can also include age, sex, comorbidities, lifestyle, preferences, circumstances, previous treatment response and patient goals. The term is broader in ordinary usage than Precision Medicine, although the two are frequently used interchangeably in scientific and policy contexts. Personalised Medicine does not imply that every patient requires a completely unique therapy. Often, it means selecting among established options according to clinically meaningful differences between individuals or subgroups. The concept therefore combines individual clinical reasoning with evidence generated from populations.
The idea has historical roots in ordinary clinical medicine because physicians have always considered individual patient characteristics when selecting treatments. Modern Personalised Medicine expanded with advances in genetics, molecular diagnostics, pharmacology, digital health and data analytics. The growing ability to measure biological variation created opportunities to move beyond one-size-fits-all treatment models. Pharmacogenomics and molecular oncology are prominent examples, but personalisation also includes risk-based prevention, individualised rehabilitation and shared decision-making. The term became increasingly prominent as medicine sought to connect large-scale research findings with individual treatment decisions. Its modern meaning therefore spans both biological stratification and broader patient-centred adaptation.
Personalisation can occur at several levels. At the biological level, genetic variants, biomarkers and physiological characteristics can guide decisions. At the clinical level, comorbidities, previous responses, organ function and disease severity affect treatment choices. At the behavioural and social level, adherence, health literacy, work demands, family circumstances and access to resources can influence whether a treatment is practical. At the preference level, patients may weigh longevity, symptom relief, independence, treatment burden and side effects differently. A genuinely personalised plan therefore requires more than collecting large amounts of data; it requires determining which differences are clinically relevant and incorporating them into a decision that remains evidence-based.
Risk prediction is an important application. Population studies can identify risk factors and develop models that estimate an individual's probability of developing a condition or experiencing an outcome. Personalised prevention may then use that estimate to determine whether closer monitoring or an intervention is appropriate. However, risk prediction is probabilistic rather than deterministic. A high predicted risk does not guarantee disease, and a low predicted risk does not eliminate the possibility. Models also require validation in populations similar to those in which they will be used because performance can deteriorate when demographic, clinical or socioeconomic characteristics differ. Personalised Medicine therefore depends on both accurate prediction and appropriate clinical interpretation.
Treatment personalisation can involve selecting a drug, dose, procedure, monitoring strategy or care pathway based on individual characteristics. Pharmacogenomic information may influence medication choice or dosing for selected medicines, while kidney or liver function may require dose adjustment independent of genetics. Previous treatment response can also guide subsequent choices, particularly in chronic disease. Shared decision-making is an important component because the medically available options may have different burdens and outcomes. Personalised Medicine therefore incorporates patient preferences without assuming that preferences override evidence about safety or effectiveness. The objective is a treatment plan that is both clinically appropriate and feasible for the person receiving it.
Data and technology increasingly support personalisation. Electronic health records can combine diagnoses, laboratory values, medications and previous outcomes, while genomic testing and wearable devices can provide additional information. Artificial intelligence and predictive modelling may identify patterns that are difficult to detect manually, but algorithmic predictions require validation and careful interpretation. Data quality, interoperability, missing information and population bias can affect performance. Personalisation can also create information overload if clinicians receive more measurements than can be meaningfully interpreted. The important distinction is between having personalised data and achieving personalised care: data become clinically useful only when they reliably change decisions in ways that improve patient outcomes.
Personalised Medicine differs from Precision Medicine primarily in breadth. Precision Medicine commonly emphasises molecular, genetic and biomarker-defined differences that allow more precise classification or treatment selection, while Personalised Medicine can encompass those factors plus clinical, behavioural, social and preference-based considerations. It also differs from patient-centred care, although the two overlap substantially; patient-centred care focuses strongly on communication, values and experience, while Personalised Medicine often includes biological stratification as well. A common misconception is that personalisation necessarily means expensive genetic testing. Many personalised decisions use ordinary clinical information, such as kidney function, age, previous treatment response or patient preference.
Personalised Medicine can improve the match between interventions and individual circumstances and may reduce ineffective treatment or unnecessary adverse effects when validated predictive information is available. Its limitations include incomplete evidence, uncertain biomarkers, data-quality problems, algorithmic bias, privacy concerns and unequal access to advanced testing. Personalisation can also become misleading if differences that are statistically detectable are treated as clinically meaningful without demonstrating benefit from acting on them. The most useful form of Personalised Medicine combines robust population evidence with relevant individual information, clinical expertise and patient preferences. It is therefore not a rejection of standardised evidence or guidelines but a method for applying appropriate evidence more intelligently to individual circumstances.
